Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2010-02-09
2010-11-02
Noakes, Suzanne M (Department: 1656)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S219000, C435S023000, C435S325000, C435S252300, C436S004000
Reexamination Certificate
active
07824897
ABSTRACT:
The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
REFERENCES:
patent: 5594106 (1997-01-01), Black et al.
patent: 5830742 (1998-11-01), Black et al.
patent: 5972331 (1999-10-01), Reichert et al.
patent: 5978740 (1999-11-01), Armistead et al.
patent: 6013466 (2000-01-01), Black et al.
patent: WO 99/40182 (1999-08-01), None
Brünger, et al. “Slow-cooling protocols for crystallographic refinement by simulated annealing”,Acta Cryst. A46:585-593 (1990).
Zask, et al. “Inhibition of matrix metalloproteinases: Structure based design”,Current Pharmaceutical Design2:624-661 (1996).
Black, et al. “A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells”,Nature385:729-733 (1997).
Moss, et al. “Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α”,Nature385:733-736 (1997).
Adams, et al. “Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement”,Proc. Natl. Acad. Soc. USA94:5018-5023 (1997).
Brünger, et al. “Crystallography & NMR System: A new software suite for macromolecular structure determination”,Acta Cryst. D54:905-921 (1998).
Maskos, et al. “Crystal structure of the catalytic domain and human tumor necrosis factor-α-converting enzyme”,Proc. Natl. Acad. Sci. USA95:3408-3412 (1998).
Schlöndorff, et al. “Metalloprotease-disintegrins: Modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding”,Journal of Cell Science112:3603-3617 (1999).
Wang, et al., “Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange™ site-directed mutagenesis”,BioTechniques26:680-682 (1999).
Qi, et al. “Minireview—Tumor necrosis factor-α-induced insulin resistance in adipocytes”,Society for Experimental Biology and Medicine223:128-135 (2000).
Black “Molecules in focus—Tumor necrosis factor-α-converting enzyme”,The International Journal of Biochemistry&Cell Biology34:1-5 (2002).
Bursi, et al. “A three-dimensional quantitative structure-activity relationship study of heparin-binding epidermal growth factor shedding inhibitors using comparative molecular field analysis”,J. Med. Chem. 45:781-788 (2002).
Letavic, et al. “Synthesis and biological activity of selective pipecolic acid-based TNF-α Converting Enzyme (TACE) Inhibitors”,Bioorganic&Medicinal Chemistry Letters12:1387-1390 (2002).
Althoff et al., “Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins.”,Eur. J. Biochem. 267(9):2624-31 (2000).
Goodsell, et al., “Automated Docking of Flexible Ligands: Applications of AutoDock”, Journal of Molecular Recognition, vol. 9, pp. 1-5, (1996).
Bohm, et al., “The computer program LUDI: A new method for the de novo design of enzyme inhibitors”, Journal of Computer-Aided Molecular Design, vol. 6, pp. 61-78 (1992).
Appendix A: Alignment of SEQ ID No. 8 and Black et al., Crystallized Protein.
McPherson, A., “Current approaches to macromolecular crystallization”, European Journal of Biochemistry, vol. 189, pp. 1-23, (1990).
Kundrot, C.E., “Which strategy for a protein crystallization project?”, Cellular Molecular Life Science, vol. 61, pp. 525-536 (2004).
Cudney R., “Protein Crystallization and Dumb Luck”, The Rigaku Journal, vol. 16, No. 1, pp. 1-7 (1999).
Ginalski, K., “Comparative modeling for protein structure prediction”, vol. 16, pp. 172-177 (2006).
Dean, P., “Recent Advances in Drug Design Methods: Where will They Lead?”, BioEssays, vol. 16, No. 9, pp. 683-687 (1994).
Beyer Brian M.
Ingram Richard N.
Orth Peter
Strickland Corey O.
Noakes Suzanne M
Schering Corp.
LandOfFree
Modified tumor necrosis factor-alpha converting enzyme and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified tumor necrosis factor-alpha converting enzyme and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified tumor necrosis factor-alpha converting enzyme and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217805